ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: SA-PO163

Effect of Menaquinone-7 Supplementation on Arterial Stiffness in Chronic Hemodialysis Patients: A Multicenter Randomized Controlled Trial

Session Information

Category: Bone and Mineral Metabolism

  • 402 Bone and Mineral Metabolism: Clinical

Authors

  • Naiyaraksaeree, Nuanjanthip, Chulalongkorn University Faculty of Medicine, Bangkok, Thailand
  • Phannajit, Jeerath, Chulalongkorn University Faculty of Medicine, Bangkok, Thailand
  • Naiyarakseree, Wichai, The Bangkok Christian Hospital, Bangkok, Bangkok, Thailand
  • Lekhyananda, Sookruetai, Kidney Foundation of Thailand, Bangkok, Bangkok, Thailand
  • Avihingsanon, Yingyos, Chulalongkorn University Faculty of Medicine, Bangkok, Thailand
  • Praditpornsilpa, Kearkiat, Chulalongkorn University Faculty of Medicine, Bangkok, Thailand
  • Eiam-Ong, Somchai, Chulalongkorn University Faculty of Medicine, Bangkok, Thailand
  • Susantitaphong, Paweena, Chulalongkorn University Faculty of Medicine, Bangkok, Thailand
Background

Vitamin K deficiency is one of the most important risk factors of vascular calcification and arterial stiffness in chronic kidney disease and dialysis patients. However,the benefit of vitamin K supplementation on structural and functional vascular health are still not established. This study was aimed to evaluate the efficacy of menaquinone-7 (MK-7) supplementation on arterial stiffness in chronic hemodialysis (HD) patients.

Methods

This open-label multicenter randomized clinical trial was conducted in 96 HD patients who had arterial stiffness, defined by high carotid femoral pulse wave velocity (cfPWV ≥ 10 m/s). The patients were randomly assigned to receive oral MK-7 (375 mcg once daily) for 24 weeks (n = 50) or standard care (control group; n = 46). The change of cfPWV was evaluated as primary outcome.

Results

The baseline parameters were comparable between two groups. At 12 weeks, patients who received MK-7 had a trend in decreasing in cfPWV compared with standard care (-13.0 ± 20.7% vs -6.8 ± 21.1%, p=0.18). This effect is more prominent in diabetes patients (-9.9±13.8% vs 1.9±17.2%, p = 0.065), In addition, the MK-7 group had lower rate of arterial stiffness progression compared with control group (21.4% vs 34.1%, p = 0.20), especially in diabetes patients (21.4% vs 58.3%, p = 0.054). There were no serious adverse events observed during 12 weeks.

Conclusion

Vitamin K supplementation provided a trend in decreasing arterial stiffness at short term follow up without serious adverse effects, especially patients with diabetes. However, the benefit on vascular heath and cardiovascular outcomes are still needed.

Funding

  • Private Foundation Support